Literature DB >> 10835686

Immunologic 'ignorance' of vascularized organ transplants in the absence of secondary lymphoid tissue.

F G Lakkis1, A Arakelov, B T Konieczny, Y Inoue.   

Abstract

Secondary lymphoid organs (the spleen, lymph nodes and mucosal lymphoid tissues) provide the proper environment for antigen-presenting cells to interact with and activate naive T and B lymphocytes. Although it is generally accepted that secondary lymphoid organs are essential for initiating immune responses to microbial antigens and to skin allografts, the prevailing view has been that the immune response to primarily vascularized organ transplants such as hearts and kidneys does not require the presence of secondary lymphoid tissue. The assumption has been that the immune response to such organs is initiated in the graft itself when recipient lymphocytes encounter foreign histocompatibility antigens presented by the graft's endothelial cells. In contrast to this view, we show here that cardiac allografts are accepted indefinitely in recipient mice that lack secondary lymphoid tissue, indicating that the alloimmune response to a vascularized organ transplant cannot be initiated in the graft itself. Moreover, we demonstrate that the permanent acceptance of these grafts is not due to tolerance but is because of immunologic 'ignorance'.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10835686     DOI: 10.1038/76267

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  129 in total

Review 1.  Routes to allograft survival.

Authors:  J S Bromberg; B Murphy
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

2.  Recall and propagation of allospecific memory T cells independent of secondary lymphoid organs.

Authors:  Geetha Chalasani; Zhenhua Dai; Bogumila T Konieczny; Fady K Baddoura; Fadi G Lakkis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

3.  A rendezvous before rejection: where do T cells meet transplant antigens?

Authors:  David M Briscoe; Mohamed H Sayegh
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

Review 4.  Transplantation tolerance from a historical perspective.

Authors:  T E Starzl; R M Zinkernagel
Journal:  Nat Rev Immunol       Date:  2001-12       Impact factor: 53.106

5.  CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism.

Authors:  Zhenhua Dai; Qi Li; Yinong Wang; Ge Gao; Lonnette S Diggs; George Tellides; Fadi G Lakkis
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

6.  Antigen location contributes to the pathological features of a transplanted heart graft.

Authors:  Yifa Chen; Yilmaz Demir; Anna Valujskikh; Peter S Heeger
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

Review 7.  CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.

Authors:  Qizhi Tang; Jeffrey A Bluestone; Sang-Mo Kang
Journal:  J Mol Cell Biol       Date:  2011-12-14       Impact factor: 6.216

Review 8.  Regulatory immune cells in transplantation.

Authors:  Kathryn J Wood; Andrew Bushell; Joanna Hester
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

9.  Preemptive CD20+ B cell depletion attenuates cardiac allograft vasculopathy in cyclosporine-treated monkeys.

Authors:  Shahrooz S Kelishadi; Agnes M Azimzadeh; Tianshu Zhang; Tiffany Stoddard; Emily Welty; Christopher Avon; Mitch Higuchi; Amal Laaris; Xiang-Fei Cheng; Christine McMahon; Richard N Pierson
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

10.  Cutting edge: Acute lung allograft rejection is independent of secondary lymphoid organs.

Authors:  Andrew E Gelman; Wenjun Li; Steven B Richardson; Bernd H Zinselmeyer; Jiaming Lai; Mikio Okazaki; Christopher G Kornfeld; Friederike H Kreisel; Seiichiro Sugimoto; Jeremy R Tietjens; John Dempster; G Alexander Patterson; Alexander S Krupnick; Mark J Miller; Daniel Kreisel
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.